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Abstract
Background and aims: Pancreaticoduodenectomy (PD) is a major operative intervention performed most commonly for
malignancy in the head of pancreas. The aim of this study was to evaluate the utilization of blood transfusion for PD and to
determine whether this had prognostic significance in a subset of patients with pancreatic ductal adenocarcinoma (PDAC).
Material and methods: Data on blood transfusion requirement were retrospectively collected for patients undergoing PD
from 1998 to 2005. Standard prognostic factors and survival data were also collected in patients with PDAC. Results: One-
hundred-and-seventy patients underwent PD. Seventy-six patients (45%) received transfusion. The median (interquartile
range) number of units of red cell concentrate (RCC) transfused perioperatively (intraoperatively and within 24 h of
surgery) was 1.5 (0.52.5). The median preoperative haemoglobin (Hb) was 126 g/dl. The median number of units of RCC
transfused perioperatively in patients with Hb B126 g/dl was 2 (13); for those with Hb]126 g/dl the median was 0 (01);
p0.003. Forty-nine patients who were resected for PDAC were subjected to survival analysis. Univariate and multivariate
analyses showed that only posterior resection margin invasion was associated with an adverse outcome (margin positive 198
[143470] days vs margin negative 398 [303859] days; p0.02). Perioperative RCC transfusion requirement was not a
significant predictor of survival (transfusion 408 [214769] days vs no transfusion 331 [217391] days; p0.18).
Furthermore, RCC transfusion within 30 days of operation was not a significant predictor of poor survival (transfusion 331
[201459] days vs no transfusion 317 [196769] days; p0.43). Conclusions: PD can be performed with a moderately low
requirement for RCC transfusion; however, low preoperative haemoglobin is a predictor for the requirement of RCC
transfusion. Administration of RCC transfusion does not appear to be a significant adverse prognostic factor in patients with
resected PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is asso-
ciated with a poor prognosis. In a study of more than
100,000 patients with PDAC, only 9% were eligible
for potentially curative resection [1]. In large tertiary
referral centres, the median survival following resec-
tion for PDAC is 1218 months with an actuarial 5-
year survival rate of 824% [26]. Reduction in
morbidity and mortality following pancreaticoduo-
denectomy (PD) has largely been attributed to sub-
specialization, greater experience and advances in
intensive care facilities [79]. Recent modest improve-
ments in long-term survival are likely related to
the use of adjuvant therapies [1012]. However,
contemporary studies report decreased use of blood
transfusions compared with earlier studies when
nearly all patients undergoing PD received periopera-
tive transfusion [13], and thus it has been suggested
that decreased perioperative blood transfusion may
also be contributory [2].
There is evidence suggesting that patients under-
going resection for PDAC who receive blood transfu-
sions have a poorer prognosis [2,3,14], although this
is not universally accepted [4,15,16]. It has been
proposed that perioperative blood transfusion induces
immunosuppression, reducing the host immune re-
sponse to tumour cells [1719], although the effect of
confounding factors, such as the technical difficulty of
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the surgery and subspecialization, make interpretation
of these data difficult.
The aim of the present study was to assess the
utilization of RCC transfusion for PD and to assess
whether perioperative RCC transfusion is an adverse
prognostic factor in resectable PDAC in a UK tertiary
referral centre.
Methods
A retrospective review was performed of all patients
who underwent PD between January 1998 and 2005.
Data were collected from a prospective database of
patients with pancreaticobiliary malignancy, retrieved
case notes, the laboratory computed results system
and the local Blood Transfusion Service database.
The transfused blood product was allogenic leucocyte
depleted red cell concentrate in all but 7 patients,
including 3 in the PDAC survival analysis.
Data collected included demographics, preopera-
tive haematological values, number of units cross-
matched, number of units transfused perioperatively
(defined as any RCC transfusion intraoperatively or
within the first 24 h of surgery), total number of units
of RCC transfused within 30 days of operation
(intraoperative transfusion plus any additional trans-
fusion within 30 days), known prognostic factors [2
6,20], final pathology, use of adjuvant therapies and
outcome including survival. In patients with PDAC,
data on the number of units of RCC transfused
preoperatively were also collected. The indication
for transfusion was left to the discretion of the
anaesthetist and surgical team responsible for the
care of the patient in the perioperative period,
although generally the trigger was significant intrao-
perative blood loss or a haemoglobin concentration of
B8 g/dl.
The utilization of RCC transfusion was analysed in
all patients undergoing PD. Analysis was carried out
to determine whether preoperative haemoglobin was
predictive of the need for perioperative transfusion.
A subset of patients with PDAC were subjected to
survival analysis to determine whether blood transfu-
sion was a significant prognostic factor in medium to
long-term survival. To ensure that preoperative hae-
moglobin was not a confounding factor in the
determinant of intraoperative transfusion, patients
were divided into two groups above and below the
median preoperative haemoglobin and this was ana-
lysed as a prognostic factor. Exclusion criteria in this
subgroup analysis included death within 30 days of
surgery.
Statistics
Statview (publishers) version 5.0.1 software was used
for statistical analysis. Nominal data are presented as
actual numbers and percentages where the denomi-
nator is50. Continuous data are presented as
median (interquartile range) and were analysed using
a Mann-Whitney U-test. Nominal data were analysed
by chi-squared test or the Fisher exact test where
appropriate. Kaplan-Meier survival curves were cre-
ated. Uni- and multivariate analyses were performed
using the log rank test and Cox proportional hazards
method, respectively, to identify independent prog-
nostic factors. A p-value ofB0.05 was deemed
significant.
Results
Utilization of RCC transfusion
Data were available on 170 patients with a median age
of 63 (5868) years who underwent PD in the period
1998 to 2005. The histopathological diagnosis was
PDAC in 62 patients, ampullary carcinoma in 38,
cholangiocarcinoma in 27, chronic pancreatitis in 10,
adenoma in 6, duodenal carcinoma in 5, neuroendo-
crine tumour in 5, cystadenocarcinoma in 3, intraduc-
tal papillary mucinous neoplasm in 3, primary
sclerosing cholangitis in 1, metastatic deposit from a
primary renal cell carcinoma in 1 patient, gastrointest-
inal stromal tumour in 1 patient and the cell of tumour
origin was indeterminate in 7. In 1 patient, a PDAC
and co-existent renal cell carcinoma were resected.
Preoperative haemoglobin levels were available on 165
patients (97%). The median number of units of RCC
cross-matched preoperatively was 4 (24).
Patient demographics, perioperative and 30-day
transfusion requirements are given in Tables I and
II. The median number of units of RCC transfused
perioperatively was 1.5 (0.52.5) and 2 in the first 30
days postoperatively (0.53.5).
Prognostic factors for patients with PDAC
Thirteen of the 62 patients with PDAC were excluded.
One patient had a co-existent renal cell carcinoma
which was treated by radical nephrectomy at the same
operation, 1 patient died within 30 days of surgery due
to pulmonary embolism and a further 11 were ex-
cluded because of incomplete data. The remaining
49 patients with PDAC had no preoperative transfu-
sions and were subjected to further analysis (Table II).
The median age of this group was 65 (5971) years,
while the median survival was 342 (130554) days.
The median preoperative haemoglobin of patients with
Table I. No. of units transfused peri-operatively (n170).
No. of units of RCC transfused peri-operatively n % of patients
0 94 55%
1 6 4%
2 45 26%
3 6 4%
4 12 7%
4 7 4%
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PDAC was 123 (115132) g/dl. The median perio-
perative (24 h) RCC transfusion requirement for
transfusion was 1.5 (0.52.5) units, while the median
30-day RCC transfusion requirement was 2 (04)
units. No patients had preoperative RCC transfusions.
Potential prognostic factors are given in Table III.
Univariate and multivariate analyses showed that only
a positive posterior resection margin was associated
with an adverse outcome (margin positive 198 [143
470] days vs margin negative 398 [303859] p0.03)
(Figure 1). Perioperative RCC transfusion require-
ment was not a significant predictor of survival
(transfusion given 408 [214769] days vs no transfu-
sion given 331 [217391] days; p0.18) (Figure 2).
Furthermore, 30-day RCC transfusion requirement
was not a significant predictor of survival (transfusion
given 331 [201459] days vs no transfusion given 317
[196769] days; p0.43) (Figure 3).
Discussion
The results of this study indicate that PD can be
performed with a moderately low requirement for
transfusion (Table I). Of 170 patients undergoing PD,
only 76 (45%) had a perioperative transfusion with a
median of 1.5 units transfused. Only 25 of 170 (15%)
patients were transfused more than 2 units. Further-
more, those at higher risk of requiring a perioperative
transfusion were those with a lower preoperative
haemoglobin level.
The results of this study indicate that survival of
patients undergoing PD for PDAC is not adversely
affected by blood transfusion, although the number of
patients included in the analysis was small, incurring
the risk of type 2 statistical error. The majority of
previous studies investigating whether blood transfu-
sion has an impact on survival in PDAC have also
Table II. Demographics of patients undergoing PD.
Variable
No of patients undergoing PD 170
Median age 63 (5868) years
Median peri-operative (24h) RCC
transfusion requirement
1.5 (0.52.5) units
Median pre-operative haemoglobin * 126 (116136) g/dl
Median peri-operative (24h)
RCC transfusion requirement
(Hb]126 g/dl)
0 (01) units
p0.003
Median peri-operative (24h)
RCC transfusion requirement
(HbB126 g/dl)
2 (13) units
Median 30 day RCC transfusion
requirement
2 (0.53.5) units
* Blood results available on 165 patients.
Results presented as median (interquartile range).
o
Table III. Prognostic factors in patients with PDAC undergoing PD
(n49).
Variable N Median Survival (IQR) P (univariate analysis)
ve lymph nodes
Yes 38 327 (170589) 0.13
No 11 434 (331954)
Posterior resection margin ve
Yes 21 198 (143470) 0.02**
No 28 398 (303859)
Resection margin ve
Yes 22 235 (164455) 0.11
No 27 420 (310756)
Tumour size 52cm
Yes 10 536 (201902) 0.23
No 39 314 (204455)
Poorly Differentiated
Yes 23 290 (191360) 0.31
No 26 434 (268848)
Pre-operative haemoglobin ]123 g/dl (median Hb 123 g/dl)
Yes 25 396 (220456) 0.19
No 24 314 (196769)
Peri-operative (24h) RCC transfusion requirement
Yes 25 408 (214769) 0.18
No 24 331 (217391)
30 day post-op RCC transfusion requirement
Yes 30 331 (201459) 0.43
No 19 317 (196769)
** Significant on multivariate analysis (p0.03).
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Figure 1. Effect of posterior margin invasion on survival of PDAC.
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Figure 2. Effect of perioperative transfusion on survival of PDAC.
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been non-randomized and relatively small, which may
explain the conflicting results [24,15,16]. The largest
study investigating the influence of blood transfusion
found that postoperative blood transfusion was an
independent predictor of survival, although on multi-
variate analysis the p-value was 0.051 [14]. Any
survival benefit that is conferred by avoiding blood
transfusion may be difficult to detect because of the
aggressive nature of PDAC and the short survival of
operated patients. In this study, it is possible that
there was incomplete recording of the number of
RCC transfusions within 30 days, with some patients
being transfused after discharge from the tertiary
referral centre. However, the majority of referring
hospitals used the same Blood Transfusion Service
database and therefore it is anticipated that the data
presented are robust.
Perioperative blood transfusion has been identified
to be an adverse prognostic factor in several malig-
nancies, including colorectal cancer [21], colorectal
cancer liver metastases [22], renal cancer [23],
osteosarcoma [24], lung cancer [25], breast cancer
[26] and prostate cancer [27]. It has been proposed
that blood transfusion is responsible for inducing
‘‘transfusion associated immunomodulation’’
(TRIM), with the resulting immunosuppression
thought to allow tumour cells to disseminate and
escape immune surveillance, thus adversely affecting
prognosis [17]. Most research in this area has been in
patients with colorectal cancer. This has been inves-
tigated by randomized control trials, although the
results are contradictory [2831]. A recent meta-
analysis of all studies investigating the effect of
perioperative blood transfusion on survival in color-
ectal cancer found this to be an adverse prognostic
factor, although there was heterogeneity between
studies [21].
Further evidence of blood transfusion exerting an
immunosuppressive effect is suggested by the im-
proved graft survival which has been observed in renal
transplant patients who receive a blood transfusion
[32]. It has also been suggested that TRIM may result
in an increased risk of infection in patients undergoing
surgery, although the evidence from randomized
control trials is conflicting [30,3337].
The mechanism by which blood transfusion leads
to immunosuppression is incompletely understood
[17], although a depression of the recipient’s cell-
mediated immunity is thought to occur with a
reduction in the number and function of T lympho-
cytes [19]. It has been demonstrated in experimental
models that donor leucocytes are responsible for
inducing immunosuppression and for allowing more
rapid tumour growth [28,32,37]. It has therefore been
hypothesized that benefit, in terms of infection rates,
hospital stay and mortality rates, could be gained by
transfusion of leucocyte-depleted blood, although
again the results are contradictory [33,34,3842].
The requirement for blood transfusion may reflect
the technical difficulty of the operative procedure,
which in turn may be due to a bulkier or more
advanced tumour which would be expected to be
associated with a poorer prognosis. Notably, one of
the studies that identified blood transfusion to be a
significant prognostic factor in PDAC commented
that the operative blood loss was also a significant
prognostic factor on multivariate analysis for long-
term survival, although this was not formally reported
in the results [3]. The current study has shown that
patients undergoing PD with a preoperative haemo-
globin level B126 mg/dl are significantly more likely
to require RCC transfusion. Lower haemoglobin
levels may be the result of other preoperative co-
morbidities, which may also explain why blood
transfusion has been found to have prognostic sig-
nificance in resected PDAC. However, the results of
this study indicate that neither the use of RCC
transfusion nor preoperative haemoglobin are signifi-
cant prognostic factors.
In conclusion, it has been shown that PD can be
performed with a moderately low requirement for
transfusion of RCC. In the past two decades, transfu-
sion requirements have reduced compared with pre-
vious years, leading to suggestions that blood
transfusion itself is responsible for decreased survival
rates and that the recent improvement in survival may
be partially attributable to this [2]. However, the
results of this study and others [4,15,16] indicate that
this is not the case. It is more likely that the
improvement in survival is the result of adjuvant
therapies and increased surgical experience through
subspecialization, with fewer patients therefore re-
quiring transfusion.
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